Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Abstract
AIM: To investigate the antitumor effect of recombinant L-asparaginase on the
growth of several tumors such as P388, L1210, hepatocellular carcinoma (Heps),
K562, P815, and sarcoma 180 (S180).
METHODS: Tumor cells (K562, L1210, and P815) were cultured in vitro and the
morphology of those cells was observed with inverse microscope and transmission
electron microscope. MTT assay was performed to measure the cell proliferation
and inhibition rate. DNA content was assayed by flow cytometry. According to
protocols of transplant tumor research, mice were transplanted with tumor cells
L1210, P388, Heps, and S180. The survival rate and weight of tumor were observed
after the treatment of test drugs.
RESULTS: The antitumor effects of L-asparaginase were observed in vitro with
tumor cells K562, L1210, and P815 (P <0.01). In vivo experiments showed that ip
administration of L-asparaginase significantly increased the survival rate and
life span of mice with P388 or L1210 tumor cells (P <0.01). Tumor growth induced
with Heps was also significantly suppressed. Furthermore, significant suppression
of tumor growth was observed in mice induced with Heps and S180 by iv
administration of L-asparaginase.
CONCLUSION: Recombinant L-asparaginase markedly inhibited tumors tested in this
study and the results strongly suggest that recombinant L-asparaginase has great
potential for clinical treatment of these tumors.
Keywords:
growth of several tumors such as P388, L1210, hepatocellular carcinoma (Heps),
K562, P815, and sarcoma 180 (S180).
METHODS: Tumor cells (K562, L1210, and P815) were cultured in vitro and the
morphology of those cells was observed with inverse microscope and transmission
electron microscope. MTT assay was performed to measure the cell proliferation
and inhibition rate. DNA content was assayed by flow cytometry. According to
protocols of transplant tumor research, mice were transplanted with tumor cells
L1210, P388, Heps, and S180. The survival rate and weight of tumor were observed
after the treatment of test drugs.
RESULTS: The antitumor effects of L-asparaginase were observed in vitro with
tumor cells K562, L1210, and P815 (P <0.01). In vivo experiments showed that ip
administration of L-asparaginase significantly increased the survival rate and
life span of mice with P388 or L1210 tumor cells (P <0.01). Tumor growth induced
with Heps was also significantly suppressed. Furthermore, significant suppression
of tumor growth was observed in mice induced with Heps and S180 by iv
administration of L-asparaginase.
CONCLUSION: Recombinant L-asparaginase markedly inhibited tumors tested in this
study and the results strongly suggest that recombinant L-asparaginase has great
potential for clinical treatment of these tumors.